Calmark signs distributor agreement with LabForce in Switzerland
Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company LabForce AG regarding marketing and sales of the Calmark POC system on the Swiss market.
The company LabForce began operations in 1999 and specializes in selling reagents and laboratory equipment for use in cellular and molecular biology, pathology and diagnostics. The company operates in the customer segments that are important to Calmark, and sells medical devices to hospitals, laboratories and the manufacturing industry.
“LabForce is a well-established distributor that is making a great effort to implement a new product line within point-of-care diagnostics. We are very proud to see Calmark's tests included in its innovative product portfolio,” says Magdalena Tharaldsen, Calmark’s Director International Business Development.
“Since Switzerland has a health care system with many private clinics, there is a need for rapid diagnostics of newborns, and we are looking forward to meet it,” says Anna Söderlund, CEO of Calmark. "We are very happy to have one more agreement concluded in Europe."
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
